A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP

This study aimed to compare the efficacy and safety of rituximab (RTX) plus recombinant human thrombopoietin (rhTPO) with RTX alone in patients with immune thrombocytopenia (ITP) who had failed to respond to corticosteroids or relapsed. Recruited patients were randomized at a ratio of 2:1 into 2 gro...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood
Главные авторы: Zhou, Hai, Xu, Miao, Qin, Ping, Zhang, Hai-yan, Yuan, Cheng-lu, Zhao, Hong-guo, Cui, Zhong-guang, Meng, Yue-sheng, Wang, Lei, Zhou, Fang, Wang, Xin, Li, Da-qi, Bi, Ke-hong, Zhu, Chuan-sheng, Guo, Cheng-shan, Chu, Xiao-xia, Wu, Qing-chao, Liu, Xin-guang, Dong, Xiao-yuan, Li, Jie, Peng, Jun, Hou, Ming
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2015
Предметы:
Clinical Trials and Observations
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4351949/
https://ncbi.nlm.nih.gov/pubmed/25575541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-06-581868
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы